Meeting Summary
Prof McElvaney opened the symposium with a brief overview of the disease history and available treatments to date for alpha-1 antitrypsin deficiency (AATD). He then introduced Dr Reeves, who gave a description of the physiological function of alpha-1 proteinase inhibitor (α1-PI), specifically its effect on neutrophil function in AATD. Dr Parr then discussed the limitations of using forced expiratory volume (FEV1) to observe lung disease progression, and the development and use of measurements of lung density as an alternative. Dr Seersholm followed with a comprehensive overview of recent clinical studies demonstrating the efficacy of α1-PI augmentation therapy. Dr Chapman gave the final presentation that expanded on this by describing the findings of the randomised, placebo-controlled trial of augmentation therapy in α1-PI deficiency (RAPID) study. The meeting objectives were to present the current treatment landscape for AATD-associated emphysema and the role of α1-PI therapy within this.
Please view the full content in the pdf above.
